Not many stocks are truly capable of generating a 1,000% return on investment within a reasonable time frame. Even so, a fair number of next-generation technology stocks have hit this lofty milestone over the years. In almost every case, the market woefully underestimated the company's core value proposition ahead of a key inflection point. A similar situation might be taking shape presently within the beaten-down gene-editing space. 

For example, CRISPR Therapeutics (NASDAQ: CRSP) has failed to earn a premium valuation despite having a diverse pipeline full of star candidates, a first-rate balance sheet, and a major partnership with Vertex Pharmaceuticals. In an article published late last month, I broke down that gene editor's dynamic risk-to-reward profile, showing that its stock might be incredibly undervalued right now. 

Here, I discuss the central investing thesis for its fellow CRISPR/Cas9 gene-editing specialist, Intellia Therapeutics (NASDAQ: NTLA). This biotech growth stock, too, stands out as a potential hidden gem.

Continue reading

Source Fool.com